Abstract
Anlotinib is a novel multi-target tyrosine kinase inhibitor approved by NMPA (China National Medical Products Administration) and its anti-tumor vascular targets include VEGFR, PDGFR, c-Kit and FGFR. This phase II study aims to further evaluate the efficacy and safety of anlotinib plus etoposide and carboplatin in treatment-naïve patients with extensive-stage small cell lung cancer (ES-SCLC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
